{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T15:21:45Z","timestamp":1792855305778,"version":"4.5.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T00:00:00Z","timestamp":1740096000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T00:00:00Z","timestamp":1740096000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1007\/s13555-025-01361-x","type":"journal-article","created":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T13:57:18Z","timestamp":1740146238000},"page":"721-731","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Indirect Comparison Between Bimekizumab and Brodalumab for the Management of Moderate to Severe Psoriasis: A 36-Week Real-Life Study"],"prefix":"10.1007","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5940-0592","authenticated-orcid":false,"given":"Luca","family":"Potestio","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabrizio","family":"Martora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Flavia","family":"Raia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gioacchino","family":"Lucagnano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudio","family":"Brescia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ginevra","family":"Torta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Megna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,21]]},"reference":[{"issue":"9997","key":"1361_CR1","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1016\/S0140-6736(14)61909-7","volume":"386","author":"WH Boehncke","year":"2015","unstructured":"Boehncke WH, Sch\u00f6n MP. Psoriasis. Lancet. 2015;386(9997):983\u201394. https:\/\/doi.org\/10.1016\/S0140-6736(14)61909-7.","journal-title":"Lancet"},{"issue":"9583","key":"1361_CR2","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/S0140-6736(07)61128-3","volume":"370","author":"CE Griffiths","year":"2007","unstructured":"Griffiths CE, Barker JN. Pathogenesis and clinical features of psoriasis. Lancet. 2007;370(9583):263\u201371. https:\/\/doi.org\/10.1016\/S0140-6736(07)61128-3.","journal-title":"Lancet"},{"key":"1361_CR3","doi-asserted-by":"publisher","unstructured":"Langley RG, Krueger GG, Griffiths CE. Psoriasis: epidemiology, clinical features, and quality of life. Ann Rheum Dis. 2005;64(Suppl 2):ii18\u201325. https:\/\/doi.org\/10.1136\/ard.2004.033217.","DOI":"10.1136\/ard.2004.033217"},{"issue":"19","key":"1361_CR4","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.1001\/jama.2020.4006","volume":"323","author":"AW Armstrong","year":"2020","unstructured":"Armstrong AW, Read C. Pathophysiology, clinical presentation, and treatment of psoriasis: a review. JAMA. 2020;323(19):1945\u201360. https:\/\/doi.org\/10.1001\/jama.2020.4006.","journal-title":"JAMA"},{"issue":"12","key":"1361_CR5","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.1080\/14712598.2022.2113872","volume":"22","author":"E Camela","year":"2022","unstructured":"Camela E, Potestio L, Fabbrocini G, Ruggiero A, Megna M. New frontiers in personalized medicine in psoriasis. Expert Opin Biol Ther. 2022;22(12):1431\u20133. https:\/\/doi.org\/10.1080\/14712598.2022.2113872.","journal-title":"Expert Opin Biol Ther"},{"issue":"3","key":"1361_CR6","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1001\/jamadermatol.2019.4029","volume":"156","author":"AW Armstrong","year":"2020","unstructured":"Armstrong AW, Puig L, Joshi A, et al. Comparison of biologics and oral treatments for plaque psoriasis: a meta-analysis. JAMA Dermatol. 2020;156(3):258\u201369. https:\/\/doi.org\/10.1001\/jamadermatol.2019.4029.","journal-title":"JAMA Dermatol"},{"issue":"11","key":"1361_CR7","doi-asserted-by":"publisher","first-page":"2461","DOI":"10.1111\/jdv.16915","volume":"34","author":"A Nast","year":"2020","unstructured":"Nast A, Smith C, Spuls PI, et al. EuroGuiDerm guideline on the systemic treatment of psoriasis vulgaris\u2014Part 1: treatment and monitoring recommendations. J Eur Acad Dermatol Venereol. 2020;34(11):2461\u201398. https:\/\/doi.org\/10.1111\/jdv.16915.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"2","key":"1361_CR8","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1111\/jdv.16926","volume":"35","author":"A Nast","year":"2021","unstructured":"Nast A, Smith C, Spuls PI, et al. EuroGuiDerm guideline on the systemic treatment of psoriasis vulgaris\u2014Part 2: specific clinical and comorbid situations. J Eur Acad Dermatol Venereol. 2021;35(2):281\u2013317. https:\/\/doi.org\/10.1111\/jdv.16926.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"4","key":"1361_CR9","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1080\/1744666X.2018.1454835","volume":"14","author":"JM Carrascosa","year":"2018","unstructured":"Carrascosa JM, Del-Alcazar E. New therapies versus first-generation biologic drugs in psoriasis: a review of adverse events and their management. Expert Rev Clin Immunol. 2018;14(4):259\u201373. https:\/\/doi.org\/10.1080\/1744666X.2018.1454835.","journal-title":"Expert Rev Clin Immunol"},{"issue":"4","key":"1361_CR10","doi-asserted-by":"publisher","DOI":"10.1111\/sji.12946","volume":"92","author":"LL Ten Bergen","year":"2020","unstructured":"Ten Bergen LL, Petrovic A, Krogh Aarebrot A, Appel S. The TNF\/IL-23\/IL-17 axis-head-to-head trials comparing different biologics in psoriasis treatment. Scand J Immunol. 2020;92(4):e12946. https:\/\/doi.org\/10.1111\/sji.12946.","journal-title":"Scand J Immunol"},{"issue":"11","key":"1361_CR11","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1080\/1744666X.2020.1679625","volume":"15","author":"K Ly","year":"2019","unstructured":"Ly K, Smith MP, Thibodeaux Q, Reddy V, Liao W, Bhutani T. Anti IL-17 in psoriasis. Expert Rev Clin Immunol. 2019;15(11):1185\u201394. https:\/\/doi.org\/10.1080\/1744666X.2020.1679625.","journal-title":"Expert Rev Clin Immunol"},{"issue":"2","key":"1361_CR12","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1007\/s13555-016-0121-x","volume":"6","author":"B Farahnik","year":"2016","unstructured":"Farahnik B, Beroukhim K, Abrouk M, et al. Brodalumab for the treatment of psoriasis: a review of phase\u00a0III trials. Dermatol Ther (Heidelb). 2016;6(2):111\u201324. https:\/\/doi.org\/10.1007\/s13555-016-0121-x.","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"5","key":"1361_CR13","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1080\/14740338.2023.2218086","volume":"22","author":"A Ruggiero","year":"2023","unstructured":"Ruggiero A, Potestio L, Martora F, Villani A, Comune R, Megna M. Bimekizumab treatment in patients with moderate to severe plaque psoriasis: a drug safety evaluation. Expert Opin Drug Saf. 2023;22(5):355\u201362. https:\/\/doi.org\/10.1080\/14740338.2023.2218086.","journal-title":"Expert Opin Drug Saf"},{"key":"1361_CR14","doi-asserted-by":"publisher","unstructured":"Gordon KB, Foley P, Krueger JG, et al. Bimekizumab efficacy and safety in moderate to severe plaque psoriasis (BE READY): a multicentre, double-blind, placebo-controlled, randomised withdrawal phase\u00a03 trial [published correction appears in Lancet. 2021 Mar 27;397(10280):1182. https:\/\/doi.org\/10.1016\/S0140-6736(21)00669-3]. Lancet. 2021;397(10273):475\u201386. https:\/\/doi.org\/10.1016\/S0140-6736(21)00126-4.","DOI":"10.1016\/S0140-6736(21)00669-3 10.1016\/S0140-6736(21)00126-4"},{"issue":"1","key":"1361_CR15","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1093\/bjd\/ljac021","volume":"188","author":"D Tha\u00e7i","year":"2023","unstructured":"Tha\u00e7i D, Vender R, de Rie MA, et al. Safety and efficacy of bimekizumab through 2\u00a0years in patients with moderate-to-severe plaque psoriasis: longer-term results from the BE SURE randomized controlled trial and the open-label extension from the BE BRIGHT trial. Br J Dermatol. 2023;188(1):22\u201331. https:\/\/doi.org\/10.1093\/bjd\/ljac021.","journal-title":"Br J Dermatol"},{"issue":"3","key":"1361_CR16","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1016\/j.jaad.2023.04.063","volume":"89","author":"B Strober","year":"2023","unstructured":"Strober B, Paul C, Blauvelt A, et al. Bimekizumab efficacy and safety in patients with moderate to severe plaque psoriasis: two-year interim results from the open-label extension of the randomized BE RADIANT phase\u00a03b trial. J Am Acad Dermatol. 2023;89(3):486\u201395. https:\/\/doi.org\/10.1016\/j.jaad.2023.04.063.","journal-title":"J Am Acad Dermatol"},{"key":"1361_CR17","doi-asserted-by":"publisher","unstructured":"Reich K, Papp KA, Blauvelt A, et al. Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase\u00a03 trial [published correction appears in Lancet. 2021 Feb 20;397(10275):670. https:\/\/doi.org\/10.1016\/S0140-6736(21)00387-1]. Lancet. 2021;397(10273):487\u201398. https:\/\/doi.org\/10.1016\/S0140-6736(21)00125-2.","DOI":"10.1016\/S0140-6736(21)00387-1 10.1016\/S0140-6736(21)00125-2"},{"issue":"1","key":"1361_CR18","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1007\/s00403-024-03594-w","volume":"317","author":"L Potestio","year":"2024","unstructured":"Potestio L, Ruggiero A, Martora F, Megna M. Long-term efficacy and safety of bimekizumab in real-world setting: a 52-week prospective study. Arch Dermatol Res. 2024;317(1):102. https:\/\/doi.org\/10.1007\/s00403-024-03594-w.","journal-title":"Arch Dermatol Res"},{"key":"1361_CR19","doi-asserted-by":"publisher","DOI":"10.1093\/ced\/llae400","author":"M Megna","year":"2024","unstructured":"Megna M, Orsini D, Assorgi C, et al. The risk of candidiasis during treatment with bimekizumab for the management of plaque psoriasis: a 16-week multicenter real-world experience\u2014IL PSO (Italian Landscape Psoriasis). Clin Exp Dermatol. 2024. https:\/\/doi.org\/10.1093\/ced\/llae400.","journal-title":"Clin Exp Dermatol"},{"issue":"1","key":"1361_CR20","doi-asserted-by":"publisher","first-page":"2393376","DOI":"10.1080\/09546634.2024.2393376","volume":"35","author":"D Orsini","year":"2024","unstructured":"Orsini D, Megna M, Assorgi C, et al. Efficacy and Safety of bimekizumab in elderly patients: real-world multicenter retrospective study\u2014IL PSO (Italian Landscape Psoriasis). J Dermatol Treat. 2024;35(1):2393376. https:\/\/doi.org\/10.1080\/09546634.2024.2393376.","journal-title":"J Dermatol Treat"},{"key":"1361_CR21","doi-asserted-by":"publisher","first-page":"1243843","DOI":"10.3389\/fmed.2023.1243843","volume":"10","author":"L Gargiulo","year":"2023","unstructured":"Gargiulo L, Narcisi A, Ibba L, et al. Effectiveness and safety of bimekizumab for the treatment of plaque psoriasis: a real-life multicenter study-IL PSO (Italian landscape psoriasis). Front Med (Lausanne). 2023;10:1243843. https:\/\/doi.org\/10.3389\/fmed.2023.1243843.","journal-title":"Front Med (Lausanne)"},{"issue":"3","key":"1361_CR22","doi-asserted-by":"publisher","first-page":"1146","DOI":"10.1111\/jocd.15543","volume":"22","author":"M Megna","year":"2023","unstructured":"Megna M, Battista T, Potestio L, et al. A case of erythrodermic psoriasis rapidly and successfully treated with bimekizumab. J Cosmet Dermatol. 2023;22(3):1146\u20138. https:\/\/doi.org\/10.1111\/jocd.15543.","journal-title":"J Cosmet Dermatol"},{"issue":"2","key":"1361_CR23","doi-asserted-by":"publisher","first-page":"e2024052","DOI":"10.5826\/dpc.1402a52","volume":"14","author":"D Orsini","year":"2024","unstructured":"Orsini D, Malagoli P, Balato A, et al. Bimekizumab for the treatment of plaque psoriasis with involvement of genitalia: a 16-week multicenter real-world experience\u2014IL PSO (Italian Landscape Psoriasis). Dermatol Pract Concept. 2024;14(2):e2024052. https:\/\/doi.org\/10.5826\/dpc.1402a52.","journal-title":"Dermatol Pract Concept"},{"issue":"10","key":"1361_CR24","doi-asserted-by":"publisher","first-page":"1378","DOI":"10.3390\/ph17101378","volume":"17","author":"E Campione","year":"2024","unstructured":"Campione E, Artosi F, Shumak RG, et al. Fast clinical response of bimekizumab in nail psoriasis: a retrospective multicenter 36-week real-life study. Pharmaceuticals (Basel). 2024;17(10):1378. https:\/\/doi.org\/10.3390\/ph17101378.","journal-title":"Pharmaceuticals (Basel)"},{"issue":"6","key":"1361_CR25","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1111\/bjd.19132","volume":"183","author":"K Papp","year":"2020","unstructured":"Papp K, Menter A, Leonardi C, et al. Long-term efficacy and safety of brodalumab in psoriasis through 120\u00a0weeks and after withdrawal and retreatment: subgroup analysis of a randomized phase\u00a0III trial (AMAGINE-1). Br J Dermatol. 2020;183(6):1037\u201348. https:\/\/doi.org\/10.1111\/bjd.19132.","journal-title":"Br J Dermatol"},{"issue":"2","key":"1361_CR26","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1016\/j.jaad.2019.05.095","volume":"82","author":"L Puig","year":"2020","unstructured":"Puig L, Lebwohl M, Bachelez H, Sobell J, Jacobson AA. Long-term efficacy and safety of brodalumab in the treatment of psoriasis: 120-week results from the randomized, double-blind, placebo- and active comparator-controlled phase\u00a03 AMAGINE-2 trial. J Am Acad Dermatol. 2020;82(2):352\u20139. https:\/\/doi.org\/10.1016\/j.jaad.2019.05.095.","journal-title":"J Am Acad Dermatol"},{"issue":"8","key":"1361_CR27","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1111\/jdv.18068","volume":"36","author":"K Reich","year":"2022","unstructured":"Reich K, Iversen L, Puig L, et al. Long-term efficacy and safety of brodalumab in moderate-to-severe plaque psoriasis: a post hoc pooled analysis of AMAGINE-2 and -3. J Eur Acad Dermatol Venereol. 2022;36(8):1275\u201383. https:\/\/doi.org\/10.1111\/jdv.18068.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1361_CR28","doi-asserted-by":"publisher","first-page":"2637","DOI":"10.2147\/CCID.S423234","volume":"16","author":"S Cacciapuoti","year":"2023","unstructured":"Cacciapuoti S, Potestio L, Guerrasio G, et al. Effectiveness of brodalumab in patients with moderate-to-severe plaque psoriasis located in difficult-to-treat areas. Clin Cosmet Investig Dermatol. 2023;16:2637\u201344. https:\/\/doi.org\/10.2147\/CCID.S423234.","journal-title":"Clin Cosmet Investig Dermatol"},{"issue":"10","key":"1361_CR29","doi-asserted-by":"publisher","first-page":"3951","DOI":"10.1007\/s12325-024-02952-4","volume":"41","author":"M Kojanova","year":"2024","unstructured":"Kojanova M, Turkova B, Gkalpakiotis S, et al. Real-world data on brodalumab treatment in patients with moderate-to-severe plaque psoriasis: an observational study from the Czech Republic BIOREP Registry. Adv Ther. 2024;41(10):3951\u201371. https:\/\/doi.org\/10.1007\/s12325-024-02952-4.","journal-title":"Adv Ther"},{"issue":"2","key":"1361_CR30","doi-asserted-by":"publisher","first-page":"e2024152","DOI":"10.5826\/dpc.1402a152","volume":"14","author":"G Caldarola","year":"2024","unstructured":"Caldarola G, Galluzzo M, Bernardini N, et al. Long-term effectiveness of brodalumab for the treatment of moderate-to-severe psoriasis: a real-life multicenter study of up to 3\u00a0years in a real-life Italian cohort. Dermatol Pract Concept. 2024;14(2):e2024152. https:\/\/doi.org\/10.5826\/dpc.1402a152.","journal-title":"Dermatol Pract Concept"},{"key":"1361_CR31","doi-asserted-by":"publisher","first-page":"829","DOI":"10.2147\/CCID.S462797","volume":"17","author":"L Potestio","year":"2024","unstructured":"Potestio L, Martora F, Lauletta G, Vallone Y, Battista T, Megna M. The role of interleukin 23\/17 axis in psoriasis management: a comprehensive review of clinical trials. Clin Cosmet Investig Dermatol. 2024;17:829\u201342. https:\/\/doi.org\/10.2147\/CCID.S462797.","journal-title":"Clin Cosmet Investig Dermatol"},{"issue":"3","key":"1361_CR32","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1007\/s12016-018-8702-3","volume":"55","author":"A Blauvelt","year":"2018","unstructured":"Blauvelt A, Chiricozzi A. The immunologic role of IL-17 in psoriasis and psoriatic arthritis pathogenesis. Clin Rev Allergy Immunol. 2018;55(3):379\u201390. https:\/\/doi.org\/10.1007\/s12016-018-8702-3.","journal-title":"Clin Rev Allergy Immunol"},{"key":"1361_CR33","doi-asserted-by":"publisher","first-page":"1682","DOI":"10.3389\/fimmu.2018.01682","volume":"9","author":"NC Brembilla","year":"2018","unstructured":"Brembilla NC, Senra L, Boehncke WH. The IL-17 family of cytokines in psoriasis: IL-17A and beyond. Front Immunol. 2018;9:1682. https:\/\/doi.org\/10.3389\/fimmu.2018.01682.","journal-title":"Front Immunol"},{"issue":"8","key":"1361_CR34","doi-asserted-by":"publisher","first-page":"694","DOI":"10.36849\/JDD.8381","volume":"23","author":"R Abdin","year":"2024","unstructured":"Abdin R, Gharib R, Bunick CG, Issa NT. Rapid remission of plaque psoriasis with bimekizumab treatment. J Drugs Dermatol. 2024;23(8):694\u20136. https:\/\/doi.org\/10.36849\/JDD.8381.","journal-title":"J Drugs Dermatol"}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-025-01361-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-025-01361-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-025-01361-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,14]],"date-time":"2025-03-14T08:04:00Z","timestamp":1741939440000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13555-025-01361-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,21]]},"references-count":34,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["1361"],"URL":"https:\/\/doi.org\/10.1007\/s13555-025-01361-x","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,21]]},"assertion":[{"value":"23 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Luca Potestio, Fabrizio Martora, Flavia Raia, Gioacchino Lucagnano, Claudio Brescia, Ginevra Torta, and Matteo Megna confirm that they have no conflicts of interest to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"The present study was conducted respecting the Declaration of Helsinki, and all patients signed an informed consent before starting the study. The patients in this manuscript have given written informed consent to publication of their case details.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}